Childhood cancer survivors who are most at risk of developing a second cancer are more likely to smoke than other childhood cancer survivors – reveals a study published in the Journal of the National Cancer Institute today.
The particular radiotherapy regimes and chemotherapy drugs used to treat children with Hodgkin’s lymphoma, soft tissue sarcomas or Wilms’ tumour are known to put these children at an increased risk of developing further new cancers than most other childhood cancer survivors.
This study of more than 10,000 childhood survivors by researchers from the Centre for Childhood Cancer Survivor Studies at the University of Birmingham shows that smoking is most common in survivors of these three types of childhood cancer.
Overall, a smaller proportion of childhood cancer survivors smoke than in the general population.
Thanks to the development of better treatments for childhood cancer, nowadays almost eight in ten children survive a diagnosis of the disease and it is estimated that there are more than 26,000 survivors of childhood cancer alive in Britain today. It is therefore vital that the health of these people is followed up later in life to reduce the impact that the long term side effects of treatment for childhood cancer can have and to improve treatments for future generations.
The study included almost 2,500 survivors of Hodgkin’s lymphoma, soft tissue sarcoma or Wilms’ tumour.
Study author, Dr Clare Frobisher, said: “Although our results show that people who survived childhood cancer are less likely to smoke than the general population, it’s clear that more work needs to be done to make sure they are aware of their increased risk of a second cancer and other related health problems if they smoke.
“It’s worrying that those survivors who are most at risk of developing a new cancer as a result of their treatment, are more likely to be smokers than other childhood cancer survivors. We hope further research will show us the best ways to reach out to this group, helping them to stop smoking, and to discourage them from starting to smoke in the first place.”
The majority of smokers in the study took up smoking before the age of 20.
Dr Frobisher continued: “We think intervention programmes should be put in place early, targeting cancer survivors as young as 12.”
It is estimated that in the UK around 11 million adults – more than one in five of the population – smoke. Overall, survivors of childhood cancer are around half as likely as the general population to be regular smokers.
Director of the Centre for Childhood Cancer Survivor Studies – which is funded by Cancer Research UK– Professor Mike Hawkins, said: “We’re very concerned that people who have been exposed to radiation and chemotherapy drugs during treatment for cancer as a child are exposing themselves to a further completely avoidable risk for developing another cancer and other smoking-related diseases in later life.”
Researchers sent out questionnaires to people enrolled on the British Childhood Cancer Survivor Study (BCCSS) – the first national study of survivors of childhood cancer to be undertaken in Britain, funded by Cancer Research UK. The BCCSS follows up nearly 18,000 people who survived a diagnosis of cancer before the age of 15 between 1940 and 1991 throughout Britain.
Cancer Research UK’s head of tobacco control, Elspeth Lee, said: “It’s crucial that young people who’ve been through treatment for childhood cancer are given all the necessary information and support to discourage them from taking up smoking, and that appropriate and targeted stop smoking advice and medication is offered to those who have already started – especially those in these high risk groups.
“Children who have been through treatment for cancer are susceptible, like all other children, to taking up smoking. The tobacco industry tries to make its products attractive to young people, which is why we’re calling for remaining forms of tobacco marketing, such as tobacco displays at the point of sale in stores, to be removed.”
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.